This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hypertension or Isolated Systolic Hypertension (ISH)
and you are
between 18 and 60
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study will evaluate the safety and tolerability of MK-8150 and its effect on central systolic blood pressure (cSBP) and heart rate corrected augmentation index (AIx) when given as single oral doses in healthy males and in males with mild-to-moderate hypertension. A primary study hypothesis is that post dose mean change from baseline of time-weighted average across 24 hours (TWA0-24hrs) cSBP or AIx is reduced in participants administered MK-8150 compared to placebo in males with mild to moderate hypertension. A mean decrease from baseline compared to placebo of ≥5 mm Hg in TWA0-24hrs cSBP or of ≥5 percentage points in TWA0-24hrs AIx is considered clinically meaningful.

Provided treatments

  • Drug: MK-8150 2.0 mg
  • Drug: MK-8150 10 mg
  • Drug: MK-8150 40 mg
  • Drug: MK-8150 90 mg
  • Drug: MK-8150 5.0 mg
  • Drug: MK-8150 20 mg
  • Drug: MK-8150 60 mg
  • Drug: MK-8150 120 mg
  • Drug: MK-8150 160 mg
  • Drug: MK-8150 320 mg
  • Drug: MK-8150 600 mg
  • Drug: MK-8150 900 mg
  • Drug: MK-8150 1200 mg
  • Drug: Placebo for MK-8150
  • Drug: MK-8150 50 mg
  • Drug: MK-8150 100 mg
  • Drug: MK-8150 200 mg
  • Drug: MK-8150 400 mg
  • Drug: MK-8150 500 mg

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01590810. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 34 volunteers for the current phase.
Official trial title:
A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150